Mitosis and apoptosis: How is the balance set?

Current Opinion in Cell Biology

Volumn 25, Issue 6, 2013, Pages 780-785

  Topham, Caroline H ^a   Taylor, Stephen S ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BH3 PROTEIN; PROTEIN BCL 2; PROTEIN MCL 1;

APOPTOSIS; CANCER CELL; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL DEATH; CELL DIFFERENTIATION; CELL DIVISION; HUMAN; M PHASE CELL CYCLE CHECKPOINT; MICROTUBULE; MITOSIS; MITOSIS INHIBITION; MYELOID LEUKEMIA; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; UPREGULATION;

ANTIMITOTIC AGENTS; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BCL-X PROTEIN; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; HUMANS; MEMBRANE PROTEINS; MICROTUBULES; MITOSIS; MODELS, BIOLOGICAL; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 84887624646     PISSN: 09550674     EISSN: 18790410     Source Type: Journal    
DOI: 10.1016/j.ceb.2013.07.003     Document Type: Review

References (46)

1. Gascoigne K.E., Taylor S.S. How do anti-mitotic drugs kill cancer cells?. J Cell Sci 2009, 122:2579-2585.
2. Jordan M.A., Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004, 4:253-265.
3. Keen N., Taylor S. Mitotic drivers-inhibitors of the Aurora B Kinase. Cancer Metastasis Rev 2009, 28:185-195.
4. Komlodi-Pasztor E., Sackett D., Wilkerson J., Fojo T. Mitosis is not a key target of microtubule agents in patient tumors. Nat Rev Clin Oncol 2011, 8:1-7.
5. Mitchison T.J. The proliferation rate paradox in antimitotic chemotherapy. Mol Biol Cell 2012, 23:1-6.
6. Marty M., Cognetti F., Maraninchi D., Snyder R., Mauriac L., Tubiana-Hulin M., Chan S., Grimes D., Anton A., Lluch A., et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005, 23:4265-4274.
7. Romond E.H., Perez E.A., Bryant J., Suman V.J., Geyer C.E., Davidson N.E., Tan-Chiu E., Martino S., Paik S., Kaufman P.A., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353:1673-1684.
8. McGrogan B.T., Gilmartin B., Carney D.N., McCann A. Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta 2008, 1785:96-132.
9. Rowinsky E.K., Eisenhauer E.A., Chaudhry V., Arbuck S.G., Donehower R.C. Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 1993, 20:1-15.
10. Lara-Gonzalez P., Westhorpe F.G., Taylor S.S. The spindle assembly checkpoint. Curr Biol 2012, 22:R966-R980.
11. Gascoigne K.E., Taylor S.S. Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell 2008, 14:111-122.
12. Rieder C.L., Maiato H. Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint. Dev Cell 2004, 7:637-651.
13. Brito D.A., Rieder C.L. Mitotic checkpoint slippage in humans occurs via cyclin B destruction in the presence of an active checkpoint. Curr Biol 2006, 16:1194-1200.
14. Brito D.A., Rieder C.L. The ability to survive mitosis in the presence of microtubule poisons differs significantly between human nontransformed (RPE-1) and cancer (U2OS HeLa) cells. Cell Motil Cytoskeleton 2009, 66:437-447.
15. Orth J.D., Tang Y., Shi J., Loy C.T., Amendt C., Wilm C., Zenke F.T., Mitchison T.J. Quantitative live imaging of cancer and normal cells treated with Kinesin-5 inhibitors indicates significant differences in phenotypic responses and cell fate. Mol Cancer Ther 2008, 7:3480-3489.
16. Shi J., Orth J.D., Mitchison T. Cell type variation in responses to antimitotic drugs that target microtubules and kinesin-5. Cancer Res 2008, 68:3269-3276.
17. Huang H.-C., Shi J., Orth J.D., Mitchison T.J. Evidence that mitotic exit is a better cancer therapeutic target than spindle assembly. Cancer Cell 2009, 16:347-358.
18. Sakurikar N., Eichhorn J.M., Chambers T.C. Cyclin dependent kinase-1 (Cdk1)/cyclin B1 dictates cell fate after mitotic arrest via phospho-regulation of anti-apoptotic Bcl-2 proteins. J Biol Chem 2012, 287:39193-39204.
19. Huang H.-C., Mitchison T.J., Shi J. Stochastic competition between mechanistically independent slippage and death pathways determines cell fate during mitotic arrest. PLoS ONE 2010, 5:e15724.
20. Lee K., Kenny A.E., Rieder C.L. Caspase activity is not required for the mitotic checkpoint or mitotic slippage in human cells. Mol Biol Cell 2011, 22:2470-2479.
21. Swanton C., Marani M., Pardo O., Warne P.H., Kelly G., Sahai E., Elustondo F., Chang J., Temple J., Ahmed A.A., et al. Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell 2007, 11:498-512.
22. Taylor S.S., McKeon F. Kinetochore localization of murine Bub1 is required for normal mitotic timing and checkpoint response to spindle damage. Cell 1997, 89:727-735.
23. Kwon M., Godinho S.A., Chandhok N.S., Ganem N.J., Azioune A., Thery M., Pellman D. Mechanisms to suppress multipolar divisions in cancer cells with extra centrosomes. Genes Dev 2008, 22:2189-2203.
24. Ring D., Hubble R., Kirschner M. Mitosis in a cell with multiple centrioles. J Cell Biol 1982, 94:549-556.
25. Allan L.A., Clarke P.R. Phosphorylation of caspase-9 by CDK1/cyclin B1 protects mitotic cells against apoptosis. Mol Cell 2007, 26:301-310.
26. Andersen J.L., Johnson C.E., Freel C.D., Parrish A.B., Day J.L., Buchakjian M.R., Nutt L.K., Thompson J.W., Moseley M.A., Kornbluth S. Restraint of apoptosis during mitosis through interdomain phosphorylation of caspase-2. EMBO J 2009, 28:3216-3227.
27. Tait S.W., Green D.R. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol 2010, 11:621-632.
28. Harley M.E., Allan L.A., Sanderson H.S., Clarke P.R. Phosphorylation of Mcl-1 by CDK1/cyclin B1 initiates its Cdc20-dependent destruction during mitotic arrest. EMBO J 2010, 29:2407-2420.
29. Wertz I.E., Kusam S., Lam C., Okamoto T., Sandoval W., Anderson D.J., Helgason E., Ernst J.A., Eby M., Liu J., et al. Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature 2011, 471:110-114.
30. Ertel F., Nguyen M., Roulston A., Shore G.C. Programming cancer cells for high expression levels of Mcl1. EMBO Rep 2013, 14:328-336.
31. Zhong Q., Gao W., Du F., Wang X. Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. Cell 2005, 121:1085-1095.
32. Ding Q., He X., Hsu J.M., Xia W., Chen C.T., Li L.Y., Lee D.F., Liu J.C., Zhong Q., Wang X., et al. Degradation of Mcl-1 by beta-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization. Mol Cell Biol 2007, 27:4006-4017.
33. Inuzuka H., Shaik S., Onoyama I., Gao D., Tseng A., Maser R.S., Zhai B., Wan L., Gutierrez A., Lau A.W., et al. SCFFBW7 regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature 2011, 471:104-109.
34. Chu R., Terrano D.T., Chambers T.C. Cdk1/cyclin B plays a key role in mitotic arrest-induced apoptosis by phosphorylation of Mcl-1, promoting its degradation and freeing Bak from sequestration. Biochem Pharmacol 2012, 83:199-206.
35. Kawabata T., Tanimura S., Asai K., Kawasaki R., Matsumaru Y., Kohno M. Up-regulation of pro-apoptotic Bim and down-regulation of anti-apoptotic Mcl-1 cooperatively mediate the enhanced tumor cell death induced by the combination of a MEK inhibitor and a microtubule inhibitor. J Biol Chem 2012, 287:10289-10300.
36. Shi J., Zhou Y., Huang H.-C., Mitchison T.J. Navitoclax (ABT-263) Accelerates Apoptosis during Drug-Induced Mitotic Arrest by Antagonizing Bcl-xL. Cancer Res 2011, 71:4518-4526.
37. Tunquist B.J., Woessner R.D., Walker D.H. Mcl-1 stability determines mitotic cell fate of human multiple myeloma tumor cells treated with the kinesin spindle protein inhibitor ARRY-520. Mol Cancer Ther 2010, 9:2046-2056.
38. Ang X.L., Wade H.J. SCF-mediated protein degradation and cell cycle control. Oncogene 2005, 24:2860-2870.
39. Terrano D.T., Upreti M., Chambers T.C. Cyclin-dependent kinase 1-mediated Bcl-xL/Bcl-2 phosphorylation acts as a functional link coupling mitotic arrest and apoptosis. Mol Cell Biol 2010, 30:640-656.
40. Upreti M., Galitovskaya E.N., Chu R., Tackett A.J., Terrano D.T., Granell S., Chambers T.C. Identification of the major phosphorylation site in Bcl-xL induced by microtubule inhibitors and analysis of its functional significance. J Biol Chem 2008, 283:35517-35525.
41. Tan N., Malek M., Zha J., Yue P., Kassees R., Berry L., Fairbrother W.J., Sampath D., Belmont L.D. Navitoclax enhances the efficacy of taxanes in non-small cell lung cancer models. Clin Cancer Res 2011, 17:1394-1404.
42. Miller A.V., Hicks M.A., Nakajima W., Richardson A.C., Windle J.J., Harada H. Paclitaxel-induced apoptosis is BAK-dependent, but BAX and BIM-independent in breast tumor. PLoS ONE 2013, 8:e60685.
43. Tan T.-T., Degenhardt K., Nelson D.A., Beaudoin B., Nieves-Neira W., Bouillet P., Villunger A., Adams J.M., White E. Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy. Cancer Cell 2005, 7:227-238.
44. Tang Y., Orth J.D., Xie T., Mitchison T.J. Rapid induction of apoptosis during Kinesin-5 inhibitor-induced mitotic arrest in HL60 cells. Cancer Lett 2011, 310:15-24.
45. Li R., Moudgil T., Ross H.J., Hu H.M. Apoptosis of non-small-cell lung cancer cell lines after paclitaxel treatment involves the BH3-only proapoptotic protein Bim. Cell Death Differ 2005, 12:292-303.
46. Kutuk O., Letai A. Displacement of Bim by Bmf and Puma rather than increase in Bim level mediates paclitaxel-induced apoptosis in breast cancer cells. Cell Death Differ 2010, 17:1624-1635.